Current Report Filing (8-k)
June 02 2021 - 9:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
June
2, 2021
Date
of Report (Date of earliest event reported)
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.
|
2431
Aloma Ave, Suite 124, Winter Park, FL
|
|
32792
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code 888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of exchange on which registered
|
Common
stock $0.0001 per share
|
|
IMUND
|
|
OTC
Markets
|
Smaller
Reporting Company [X]
Indicate
by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act: Yes [ ] No [X]
Item
8.01. Other Events.
On
May 25, 2021, Immune Therapeutics, Inc. (the “Company”) entered into a non-binding Letter of Intent with certain of the Company’s
existing investors. Readers should refer to the Letter of Intent filed as an exhibit to this Form 8-K to review all of the terms and
conditions of the Letter of Intent. The primary terms of this non-binding Letter of Intent are:
-
The investors will lend a minimum of $700,000 and a maximum of $1,500,000 to the Company in exchange for non-convertible promissory notes
bearing interest at 5%.
-
Each lender will sign a 12-month lock-up agreement.
In
connection with the transactions above, certain amounts owed to former employees, current management and directors, and other accounts
payable will be renegotiated. Closing of the transactions contemplated by the Letter of Intent are subject to a number of conditions
being satisfied, including the completion of due diligence.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
|
Date:
June 2, 2021
|
By:
|
/s/
Kevin J. Phelps
|
|
|
Kevin
J. Phelps, Chief Executive Officer, Director
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024